deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT00435916

Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma

A Phase II Study of SGN-40 (Anti-huCD40 mAb) in Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)

Sponsor: Genentech, Inc.

Interventions SGN-40
Updated 9 times since 2017 Last updated: Dec 17, 2014 Started: Dec 31, 2006 Primary completion: Jan 31, 2009 Completion: Jan 31, 2009
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Lymphoma, Large B-Cell, Diffuse and Lymphoma, Non-Hodgkin, this trial is completed. The trial is conducted by Genentech, Inc. and has accumulated 9 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Nov 2020 · 29 months · monthly snapshotCompleted~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshotCompleted~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshotCompleted~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 12 months · monthly snapshotCompleted

Change History

9 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE2

Show 4 earlier versions
  1. Nov 2020 — Jan 2021 [monthly]

    Completed PHASE2

  2. Jun 2018 — Nov 2020 [monthly]

    Completed PHASE2

  3. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Dec 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Genentech, Inc.
  • Seagen Inc.
Data source: Seagen Inc.

For direct contact, visit the study record on ClinicalTrials.gov .